(Q39535140)

English

Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.

scientific article published on 16 August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Michele Caraglia

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Pierpaolo Correale

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Maria Grazia Cusi

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Gianni Gori Savellini

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

M T Del Vecchio

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

M M De Santi

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

E Bestoso

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

S Apollinari

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

S Mannucci

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

M Marra

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

A Abbruzzese

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

A Aquino

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

M Turriziani

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

L Bonmassar

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

P Tagliaferri

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

0 references

publication date

16 August 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

International Journal of Cancer

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

130

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1577-1589

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21618510%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

The ErbB signaling network: receptor heterodimerization in development and cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Epidermal growth factor receptor (EGFR) signaling in cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Tyrosine kinase receptor-activated signal transduction pathways which lead to oncogenesis.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Epidermal growth factor receptor inhibitors in colorectal cancer treatment: what's new?

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor positive tumor cells is enhanced by cytokines

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC).

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Antitumor antibodies in the treatment of cancer: Fc receptors link opsonic antibody with cellular immunity

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Inducing tumor immunity through the selective engagement of activating Fcgamma receptors on dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5-fluorouracil, and leucovorin, elicits a powerful human antigen-specific CTL re

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Single cell analyses of cytokine production

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Treatment of colon and breast carcinoma cells with 5-fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA-A(*)02.01 restricted, CEA-peptide-specific cytotoxic T cells in vitro

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

ERP57 membrane translocation dictates the immunogenicity of tumor cell death by controlling the membrane translocation of calreticulin

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Enhanced T-cell responses to glioma cells coated with the anti-EGF receptor antibody and targeted to activating FcgammaRs on human dendritic cells

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased Raf-1 ubiquitin-dependent degradation

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Beta-lactam activity against resistant pneumococcal strains is enhanced by the immune system.

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Complement and cellular cytotoxicity in antibody therapy of cancer

1 reference

https://api.crossref.org/works/10.1002%2FIJC.26181

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39535140&oldid=1790200009"